CLOSED
GET A PIECE OF ONEFUL HEALTH, INC.
Show more
Edison T Hudson • CEO/CTO/Board Member/Founder
(Fulltime Employee)
Read More
Danny M Barnes • Chief Pharmacy Officer, Board Member, President Triangle Compounding Pharmacy
(Fulltime Employee)
Read More
Deon Joubert • Chairman of Board
(Outside Board Member)
Read More
the pitch
OneFul Health's mission is to improve the quality of life for millions of patients, through personalized medicine produced with patented pharmacy technology. Our e-pharmacy platform combines precision medicine science and robotic automation to create multi-drug prescriptions as a capsule or easy-to-swallow gel packet. The company is currently focused on launching its personalized “polypill” product for cardiovascular patients and plans to scale to additional markets and health conditions, including mental health and diseases of aging, in the next few years.
OneFul’s pharmaceutical technology platform is being designed to offer affordable and accessible prescription combination medications, customizable to a variety of health conditions and chronic diseases at the individual level.
*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.
Utilizing patented processes and innovative drug delivery technology, our digital platform is designed to consolidate many approved medications into a single capsule format, with a goal of improving patient adherence, and reducing any adverse effects from treatment. Our regulatory licenses allow us to go to market now without the uncertainty of government approvals using approved pharmaceuticals in high-purity forms. We work with partners who supply genomic analysis and digital health data, and algorithms to formulate each prescription to be the most effective combination of treatments possible for each person.
The Problem & Our Solution
For consumers managing chronic diseases and conditions, current drug therapies typically consist of multiple medications, requiring patients to take as many as 3-7 pills per day. According to recent data, 24% of adults in the U.S. take more than 3 pills per day and the rate of adherence to prescribed treatments is less than 50% (source, source), resulting in at least 100,000 preventable deaths, and $100B in preventable medical costs per year. (source)
In order to consolidate existing prescriptions as well as improve treatment outcomes, OneFul has developed the technology to combine multiple approved drugs and produce a single small capsule or flavored gel packets, containing high-purity doses of the same active drug ingredients.
*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.
Our patented automation platform is capable of producing formulas on-demand, more accurately, and up to 100 times faster than traditional manual compounding, resulting in low-cost, highly-customized, multi-drug treatments. Many of our products cost as little as $1 per day and can be additionally personalized with microdosing to best suit the drug metabolism of each individual patient.
The Market & Our Traction
OneFul’s e-pharmacy has built a customer base of over loyal 3,500 patients, generating annual revenues of over $5M. 15-20% of existing customers surveyed indicate an interest in the cardiovascular polypill concept, translating to a potential waitlist of hundreds. We are in the process of negotiating contractual relationships with partners that include physician telemedicine networks, cardiology specialists, concierge clinics, and has had development contracts with major hospital systems.
In order to meet growing demand, OneFul is building a direct-to-patient ecommerce platform, and, at present, the company has secured more than 13 patents for its robotic automation, personalized medicine process methods, and pharma-tech. Our strategic roadmap entails automation of 500 unique scripts per month by Q3 of 2023, and we believe we may incrementally increase monthly capacity to 5K by Q4 and 10K by mid-2024.
*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.
Why Invest
In OneFul’s opinion, we possess a unique opportunity built on an accredited established business combined with unmatched IP and innovation. We are on track to serve thousands of existing customers, and to reach millions of chronic disease sufferers, improving their health and daily quality of life.
As of 2021, the company had successfully raised over $7M in funding which has been instrumental in developing our IP and building a commercial operation.
Our future plans include market promotion, new partnerships, and scaling existing production operations to accommodate the growing demand for personalized therapies. Thank you for your investment in OneFul Health!
Click here to see if you qualify for our polypill!